NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




GU Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Prostate

ECOG-ACRIN EA8153 - "Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial"

CANCER TYPE: Prostate
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT03419234
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Prostate adenoca, progressive, soft tissue and/or bone mets, previous docetaxel, androgen deprivation and abiraterone and prednisone +/- cabazitaxel.






NRG-GU002 - "PHASE II-III TRIAL OF ADJUVANT RADIOTHERAPY AND ANDROGEN DEPRIVATION FOLLOWING RADICAL PROSTATECTOMY WITH OR WITHOUT ADJUVANT DOCETAXEL"

CANCER TYPE: Prostate
RESEARCH BASE: NRG
NCT NUMBER: NCT03070886
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Post-prostatectomy, baseline Gleason ≥ 7, any pT, pN0 or pNX, no distant mets, adj. RT and androgen deprivation, with or without adj. docetaxel.






RTOG 0924 - "ANDROGEN DEPRIVATION THERAPY AND HIGH DOSE RADIOTHERAPY WITH OR WITHOUT WHOLE-PELVIC RADIOTHERAPY IN UNFAVORABLE INTERMEDIATE OR FAVORABLE HIGH RISK PROSTATE CANCER: A PHASE III RANDOMIZED TRIAL"

CANCER TYPE: Prostate
RESEARCH BASE: NRG
NCT NUMBER: NCT01368588
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Prostate adenoca, moderate to high risk for recurrence, clinically negative lymph nodes, no bone mets, neoadj. androgen deprivation therapy and high dose RT w/wo whole pelvic RT.






Renal



  © 2013-2018 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA